Literature DB >> 24430804

A quiet revolution in global public health: The World Health Organization's Prequalification of Medicines Programme.

Ellen F M 't Hoen1, Hans V Hogerzeil2, Jonathan D Quick3, Hiiti B Sillo4.   

Abstract

Problems with the quality of medicines abound in countries where regulatory and legal oversight are weak, where medicines are unaffordable to most, and where the official supply often fails to reach patients. Quality is important to ensure effective treatment, to maintain patient and health-care worker confidence in treatment, and to prevent the development of resistance. In 2001, the WHO established the Prequalification of Medicines Programme in response to the need to select good-quality medicines for UN procurement. Member States of the WHO had requested its assistance in assessing the quality of low-cost generic medicines that were becoming increasingly available especially in treatments for HIV/AIDS. From a public health perspective, WHO PQP's greatest achievement is improved quality of life-saving medicines used today by millions of people in developing countries. Prequalification has made it possible to believe that everyone in the world will have access to safe, effective, and affordable medicines. Yet despite its track record and recognized importance to health, funding for the programme remains uncertain.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430804     DOI: 10.1057/jphp.2013.53

Source DB:  PubMed          Journal:  J Public Health Policy        ISSN: 0197-5897            Impact factor:   2.222


  7 in total

1.  Bush accused of blocking access to cheap AIDS drugs.

Authors:  Owen Dyer
Journal:  BMJ       Date:  2004-04-03

2.  Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.

Authors:  Brenda Waning; Margaret Kyle; Ellen Diedrichsen; Lyne Soucy; Jenny Hochstadt; Till Bärnighausen; Suerie Moon
Journal:  Global Health       Date:  2010-05-25       Impact factor: 4.185

3.  Generics for AIDS.

Authors: 
Journal:  Nat Immunol       Date:  2004-11       Impact factor: 25.606

Review 4.  Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review.

Authors:  Jennie Connor; Natasha Rafter; Anthony Rodgers
Journal:  Bull World Health Organ       Date:  2005-01-05       Impact factor: 9.408

5.  The important world of drug prequalification.

Authors: 
Journal:  Lancet       Date:  2004 Nov 20-26       Impact factor: 79.321

6.  Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.

Authors:  Christian Laurent; Charles Kouanfack; Sinata Koulla-Shiro; Nathalie Nkoué; Anke Bourgeois; Alexandra Calmy; Bernadette Lactuock; Viviane Nzeusseu; Rose Mougnutou; Gilles Peytavin; Florian Liégeois; Eric Nerrienet; Michèle Tardy; Martine Peeters; Isabelle Andrieux-Meyer; Léopold Zekeng; Michel Kazatchkine; Eitel Mpoudi-Ngolé; Eric Delaporte
Journal:  Lancet       Date:  2004 Jul 3-9       Impact factor: 79.321

Review 7.  Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

Authors:  Ellen 't Hoen; Jonathan Berger; Alexandra Calmy; Suerie Moon
Journal:  J Int AIDS Soc       Date:  2011-03-27       Impact factor: 6.707

  7 in total
  31 in total

1.  Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons.

Authors:  Luther Gwaza; John Gordon; Henrike Potthast; Jan Welink; Hubert Leufkens; Matthias Stahl; Alfredo García-Arieta
Journal:  Eur J Clin Pharmacol       Date:  2015-06-24       Impact factor: 2.953

2.  Viewpoint: Counterfeit medicines and substandard medicines: Different problems requiring different solutions.

Authors:  Ellen 't Hoen; Fernando Pascual
Journal:  J Public Health Policy       Date:  2015-07-16       Impact factor: 2.222

3.  Global Harmonization of Comparator Products for Bioequivalence Studies.

Authors:  Luther Gwaza; John Gordon; Hubert Leufkens; Matthias Stahl; Alfredo García-Arieta
Journal:  AAPS J       Date:  2017-03-06       Impact factor: 4.009

Review 4.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

5.  Tough decisions on essential medicines in 2015.

Authors:  Nicola Magrini; Jane Robertson; Gilles Forte; Bernadette Cappello; Lorenzo P Moja; Kees de Joncheere; Marie-Paule Kieny
Journal:  Bull World Health Organ       Date:  2015-03-12       Impact factor: 9.408

6.  Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.

Authors:  Vincent Ahonkhai; Samuel F Martins; Alexandre Portet; Murray Lumpkin; Dan Hartman
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

7.  Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy.

Authors:  Raffaella Ravinetto; Daniel Vandenbergh; Cécile Macé; Corinne Pouget; Brigitte Renchon; Jean Rigal; Benedetta Schiavetti; Jean-Michel Caudron
Journal:  J Pharm Policy Pract       Date:  2016-11-10

8.  Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility.

Authors:  Kaspars Lunte; Thierry Cordier-Lassalle; Joel Keravec
Journal:  Bull World Health Organ       Date:  2015-02-27       Impact factor: 9.408

Review 9.  Combating poor-quality anti-malarial medicines: a call to action.

Authors:  Quique Bassat; Marcel Tanner; Philippe J Guerin; Kirstin Stricker; Kamal Hamed
Journal:  Malar J       Date:  2016-06-01       Impact factor: 2.979

10.  The Global Drug Facility as an intervention in the market for tuberculosis drugs.

Authors:  Nimalan Arinaminpathy; Thierry Cordier-Lassalle; Kaspars Lunte; Christopher Dye
Journal:  Bull World Health Organ       Date:  2015-03-03       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.